ACROBiosystems has developed a series of recombinant cytokines including interleukins, growth factors, tumor necrosis factors (TNFs), chemokines, colony-stimulating factors (CSFs), interferons (IFNs), complement factors and other receptor proteins with high quality, high purity, high bioactivity and high batch-to-batch consistency, which are suitable for targeted drug development, functional evaluation and quality control.

● VEGF is involved in the development of many diseases and is expressed in a variety of malignancies, thus making it a prospect target for drug development.

● The combination of VEGF with other targets such as (PD-1/PD-L1, ANG-2) provides clinical benefits for cancer patients.

● ACROBiosystems provides a comprehensive range of high-quality VEGF and VEGF receptor proteins.

● Activation of the IGF-IR pathway is critical for cancer initiation and growth, and many types of tumor cells overexpress IGF-IR, leading to resistance to radiotherapy, chemotherapy and targeted therapies in a variety of cancers.

● Combined targeting of IGF-IR and STAT3 may inhibit tumor metastasis and overcome resistance to STAT3-mediated anti-IGF-IR therapy, improving the efficacy of cancer treatment.

● ACROBiosystems provides a comprehensive range of high quality IGF and IGF receptor proteins.